Patricia Wu
Endocrinology, Diabetes & Metabolism · San Diego, CANPI 1619054236
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (51.9%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Eli Lilly at 59.8% of the total. 2025 is the largest year on record at $3,241, 7.1 times the $457 reported in 2019.
Across 45 payments — averaging $100.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$3K
- Radius Health, Inc.$304
- BETA Bionics, Inc.$245
- Corcept Therapeutics$205
- Sentynl Therapeutics, Inc.$193
- AstraZeneca$192
- plus $675 from 5 others
Across 14 payments — averaging $11,329 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$147K
- Eli Lilly$7K
- Radius Health, Inc.$3K
- Merck$1K
What the payments were for
- Consulting fees$1934%
- Travel & lodging$2,34552%
- Food & beverage$1,97744%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 22 | $2,702 |
| Radius Health, Inc. | 6 | $304 |
| BETA Bionics, Inc. | 3 | $245 |
| Corcept Therapeutics | 3 | $205 |
| Sentynl Therapeutics, Inc. | 1 | $193 |
| AstraZeneca | 2 | $192 |
| Tandem Diabetes Care, Inc. | 2 | $169 |
| Janssen Scientific Affairs, LLC | 2 | $154 |
| Sanofi-aventis U.S. LLC | 2 | $123 |
| Abbott | 1 | $116 |
| Amgen | 1 | $112 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,515 in reported general payments places this provider in the 70th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ForteoTeriparatide | 81 | $111,441 |
| OzempicSemaglutide | 68 | $58,968 |
| HumalogInsulin Lispro | 61 | $15,600 |
| OmnitropeSomatropin | 49 | $13,734 |
| Humalog Kwikpen U-100Insulin Lispro | 45 | $12,921 |
| Levothyroxine Sodium | 684 | $12,822 |
| TradjentaLinagliptin | 12 | $12,279 |
| JardianceEmpagliflozin | 18 | $9,289 |
| Alendronate Sodium | 139 | $9,260 |
| Insulin Glargine-Yfgn | 61 | $6,876 |
| Liraglutide | 12 | $6,612 |
| Testosterone | 81 | $6,108 |
| Hydrocortisone | 51 | $4,498 |
| Methimazole | 192 | $3,965 |
| Liothyronine Sodium | 46 | $2,617 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in San Diego
- Juan FriasSan Diego$1.4M
- Ken FujiokaSan Diego$747K
- Raymond PlodkowskiSan Diego$546K
- Jeremy PettusSan Diego$493K
- Samantha HarrisSan Diego$113K
- Suvesh ChandiokSan Diego$71K
- Schafer BoederSan Diego$60K
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.